Facebook
Twitter
LinkedIn
ForwardMonthly Oncology Tumor Boards: Uveal Melanoma: Treatment of Metastatic Disease
The management of metastatic uveal melanoma still presents a major clinical challenge among physicians. Since the most common site of metastasis is the liver, and efficient management of liver metastases can improve disease outcome, it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel. Uveal melanoma can also metastasize to sites other than the liver, and while existing treatment options are limited, recent exciting clinical trial results offer hope for these patients.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Identify disease and patient characteristics indicative of poor prognoses for metastatic uveal melanoma.
- Outline treatment options for patients with metastatic uveal melanoma.
- Summarize existing challenges to the treatment of patients with metastatic uveal melanoma.
Miguel A. Materin, MD
Duke Cancer Institute
Harriet Kluger, MD
Yale Cancer Center/Smilow Cancer Hospital
Mario Sznol, MD
Yale Cancer Center/Smilow Cancer Hospital
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Miguel A. Materin, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Castle Biosciences, Inc.: Consulting Fee
IDEAYA Biosciences: Consulting Fee
Harriet Kluger, MD
Apexigen: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Calithera Biosciences, Inc.: Consulting Fee
ChemoCentryx, Inc.: Consulting Fee
Clinigen: Consulting Fee
GigaGen, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Pliant Therapeutics: Consulting Fee
Signatera: Consulting Fee
Mario Sznol, MD
Adagene: Consulting Fee
Adaptimmune Therapeutics plc: Consulting Fee
Adaptive Biotechnologies: Equity Interest/Stock Options
Actym Therapeutics, Inc.: Equity Interest/Stock Options
Agenus Inc.: Consulting Fee
Alligator Bioscience: Consulting Fee
Amphivena Therapeutics: Equity Interest/Stock Options
Apexigen: Consulting Fee
Asher Biotherapeutics, Inc.: Equity Interest/Stock Options
AstraZeneca Pharmaceuticals LP: Consulting Fee
Biond Biologics: Consulting Fee
BioNTech SE: Consulting Fee
Boston Pharmaceuticals: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Dragonfly Therapeutics, Inc.: Consulting Fee
EvolveImmune Therapeutics: Equity Interest/Stock Options
Evaxion Biotech AS: Consulting Fee
Genentech – Roche: Consulting Fee
Genocea Biosciences: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
GlaxoSmithKline: Equity Interest/Stock Options
Idera Pharmaceuticals, Inc.: Consulting Fee
Immunocore Ltd.: Consulting Fee
Incyte Corporation: Consulting Fee
Innate Pharma S.A.: Consulting Fee
Intensity Therapeutics: Equity Interest/Stock Options
ITeos Therapeutics: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee
Johnson & Johnson: Equity Interest/Stock Options
Kadmon – Sanofi: Consulting Fee
Kanaph Therapeutics: Consulting Fee
Laboratoires Pierre Fabre: Consulting Fee
Molecular Partners AG: Consulting Fee
NextCure, Inc.: Equity Interest/Stock Options
Normunity Inc.: Consulting Fee; Equity Interest/Stock Options
Numab Therapeutics AG: Consulting Fee
Ocellaris – Lilly: Consulting Fee
OncoHost: Equity Interest/Stock Options
OncoSec Medical: Consulting Fee
Ontario Institute for Cancer Research: Consulting Fee
Pfizer Inc.: Consulting Fee
PIO Therapeutics: Consulting Fee
Pliant Therapeutics: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee
Repertoire Immune Medicines: Equity Interest/Stock Options
Rootpath, Inc.: Equity Interest/Stock Options
Rubius Therapeutics, Inc: Consulting Fee
Sapience Therapeutics, Inc.: Consulting Fee
Servier Pharmaceuticals: Consulting Fee
Simcha Therapeutics: Consulting Fee
STCube Inc.: Consulting Fee
Targovax: Consulting Fee
Tessa Therapeutics Ltd.: Consulting Fee
Verastem Oncology: Consulting Fee
Xilio Therapeutics: Consulting Fee
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-027-L01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00054479; Approval #: 230000928
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Price
This webinar was presented live one time only on Monday, April 10, 2023, from 3:00 – 4:00 PM EDT (UTC -4).
The recorded webcast is available here.
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing